**HPV Type 16 E7 Monoclonal Antibody (8C9)**

**Catalog Number** 28-0006

<table>
<thead>
<tr>
<th>Details</th>
<th>Species Reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>50 µg</td>
</tr>
<tr>
<td>Host/Isotope</td>
<td>Mouse / IgG1</td>
</tr>
<tr>
<td>Class</td>
<td>Monoclonal</td>
</tr>
<tr>
<td>Type</td>
<td>Antibody</td>
</tr>
<tr>
<td>Clone</td>
<td>8C9</td>
</tr>
<tr>
<td>Immunogen</td>
<td>Bacterially derived fusion protein containing the human papillomavirus type 16 early protein E7 open reading frame.</td>
</tr>
</tbody>
</table>

**Tested Applications**

- **Immunohistochemistry (Paraffin)**
  - Dilution: 1:2
- **Immunoprecipitation (IP)**
  - Dilution: 1:10
- **Western Blot (WB)**
  - Dilution: 1:100

**Published Applications**

- **Western Blot (WB)**
  - See 13 publications below
- **Immunoprecipitation (IP)**
  - See 2 publications below
- **Immunocytochemistry (ICC/IF)**
  - See 6 publications below
- **Miscellaneous PubMed (Misc)**
  - See 1 publications below

**Published species**: Virus

**Species reactivity**: Virus

**Immunogen**: Bacterially derived fusion protein containing the human papillomavirus type 16 early protein E7 open reading frame.

**Conjugate**: Unconjugated

**Form**: Lyophilized

**Concentration**: 50 µg/mL

**Purification**: HPLC

**Storage buffer**: PBS with 1% BSA

**Contains**: 0.1% sodium azide

**Storage Conditions**: 4°C

**Suggested working dilutions** are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.

**For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.**
## PubMed References For HPV Type 16 E7 Monoclonal Antibody (8C9)

<table>
<thead>
<tr>
<th>Species / Dilution</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virus / Not Cited</td>
<td>28-0006 was used in Western Blot to demonstrate that pRB degradation is a direct activity of E7 and does not reflect a property of cell lines acquired during the selection process for E7 expression.</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>&quot;Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.&quot; Author(s): Gonzalez SL, Stremial M, He X, Basile JR, Münger K PubMed Article URL: dx.doi.org/10.1128/JVI.75.16.7583-7591.2001</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>28-0006 was used in Western Blotting to study how human papillomavirus oncoproteins E6 and E7 manipulate cellular signalling cascades to promote the viral life cycle and cancer development.</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>&quot;The Human Papillomavirus 16 E7 Oncoprotein Attenuates AKT Signaling To Promote Internal Ribosome Entry Site-Dependent Translation and Expression of c-MYC.&quot; Author(s): Strickland SW, Vande Pol S PubMed Article URL: dx.doi.org/10.1128/JVI.00411-16</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>28-0006 was used in Western Blot to indicate that either HRAS mutation or activation of EGFR in cooperation with MYC overexpression play critical roles in transformation of HTKs on a background of inactivation of the pRB and p53 pathways and telomerase activation.</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>28-0006 was used in Western blotting to study the use of vesicular stomatitis virus as a platform for the oncolytic immunovirotherapy of tumours expressing HPV target antigens.</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>28-0006 was used in Western Blot to study the development and pre-clinical testing of a vaccine candidate consisting of replication-deficient adenovirus type 26 and 35 based vectors for the interception of HPV16- and HPV18-related disease.</td>
</tr>
<tr>
<td>Virus / Not Cited</td>
<td>28-0006 was used in Western Blot to suggest that DLG4 may function as a tumor suppressor in the development of HPV-associated cancers.</td>
</tr>
</tbody>
</table>

28-0006 was used in Western Blotting to show that glutamate-rich WD40 repeat containing 1 physically and functionally interacts with ribosomal protein L11.

Virus / Not Cited

EMBO reports (Jan 2017; 18: 123)

"GRWD1 negatively regulates p53 via the RPL11-MDM2 pathway and promotes tumorigenesis."


PubMed Article URL:http://dx.doi.org/10.15252/embr.201642444

2 Immunoprecipitation References

Species / Dilution Summary

Nature genetics (Aug 2015; 47: 933)

"Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes."

Author(s):Hobbs RP,DePianto DJ,Jacob JT,Han MC,Chung BM,Bataazzi AS,Poll BG,Guo Y,Han J,Ong S,Zheng W,Taube JM,ihaková D,Janofsky M,Prensky A

PubMed Article URL:http://dx.doi.org/10.1038/ng.3355

6 Immunocytochemistry References

Species / Dilution Summary

Oncogene (Jun 2015; 20: 3629)

"The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts."

Author(s):Thompson DA,Lee J,Abid S,Mochnick S,Shields MA,Shenkein A,Weiss JA,Goldberg MA

PubMed Article URL:http://dx.doi.org/10.1038/onc.2013.426


Products are warranted to operate or perform satisfactorily in conformance with published Product specifications in effect at the time of sale, as set forth in the Product documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, all claims of suitability for use in applications regulated by FDA are limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. The warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample.

NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. NO WARRANTY EXISTS FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD (LIMITED TO REPAIRS, REPLACEMENT OR REFUND FOR THE NON-CONFORMING PRODUCTS) AT SELLER’S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, damage or event of force majeure, (II) misuse, fault or negligence of or by Buyer, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS; unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unapproved commercial uses, in vitro diagnostic uses, in vivo therapeutic uses, or any type of consumption by or application to human or animals.
28-0006 was used in immunocytochemistry and western blot to investigate the localization of E7 from human papillomavirus type 16

**Virus / Not Cited**

PloS one (Dec 2011; 6: )

"Localisation of human papillomavirus 16 E7 oncoprotein changes with cell confluence."

Author(s): Laurson J, Raj K

PubMed Article URL: http://dx.doi.org/10.1371/journal.pone.0021501

**Virus / Not Cited**

Cell (Oct 2002; 111: 29)

"The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini."

Author(s): Deb Nath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS

PubMed Article URL: http://dx.doi.org/10.1016/s0092-8674(02)01001-2

**Virus / Not Cited**

Journal of virology (Jun 2012; 86: 6358)

"Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression."

Author(s): Isaacson Wechsler E, Wang Q, Roberts I, Pagliarulo E, Jackson D, Un ter sperger C, Coleman N, Griffin H, Doorbar J

PubMed Article URL: http://dx.doi.org/10.1128/JVI.07069-11

**Virus / Not Cited**


"Preservation of the myofibroblastic phenotype of human papilloma virus 16 E6/E7 immortalized human bone marrow cells using the lineage limited alpha-smooth muscle actin promoter."

Author(s): Loeuillet C, Douay L, Hervé P, Chalmers DE


**1 Miscellaneous PubMed References**

**Species / Dilution**

Summary

28-0006 was used in immunocytochemistry to study the response of auditory and balance hair cells to forced cell cycle reactivation and p53 up-regulation.

**Virus / 1:25**

Journal of neurochemistry (Mar 2010; 112: 1513)

"Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re-entry and p53 induction."

Author(s): Sulg M, Kirjavainen A, Pajusola K, Bueler H, Ylikoski J, Laiho M, Pirvola U

PubMed Article URL: http://dx.doi.org/10.1111/j.1471-4159.2009.06563.x